Berberine, a herbal alkaloid, may serve as a therapeutic agent for Vulvovaginal candidiasis by inhibiting the adhesion of Candida to vaginal epithelial cells.
The method applied in this study focused on assessing the impact of Berberine(BBR), a herbal alkaloid, on the adhesion of Candida to vaginal epithelial cells. By observing the reduction in expressions of adhesion-modulating elements such as ICAM-1, mucin1, and mucin4 within the vaginal epithelial cells and by measuring the balance between IL-2 and IL-4 expressions, the research team could identify how BBR impacts the behavior of this fungus.
Discussion of the findings indicated that BBR indeed significantly hinders the adhesion of Candida to vaginal epithelial cells. This inhibitory effect is largely due to the decreased expressions of ICAM-1, mucin1, and mucin4 in vaginal epithelial cells, which are integral to the adhesive properties of the fungus. Furthermore, BBR was found to adjust IL-2 and IL-4 expression levels, which are key to controlling the inflammatory response induced by a Candida infection. This evidence suggests the potential of BBR as a novel approach to Vulvovaginal candidiasis treatment, specifically in the development of new antifungal therapies derived from natural herbs.
